^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
C-13-60
i
Other names: C-13-60, CEA-targeted CAR-T therapy, C1360, C 13 60
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Chongqing Precision Biotech
Drug class:
CEA-targeted CAR-T immunotherapy
Related drugs:
9d
PBC102: A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors (clinicaltrials.gov)
P1, N=48, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
New P1 trial
|
cyclophosphamide • fludarabine IV • C-13-60
10d
CEA CAR-T Therapy After Cytoreduction in Colorectal Cancer Patients With Peritoneal Metastases (clinicaltrials.gov)
P1, N=12, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
New P1 trial
|
cyclophosphamide • fludarabine IV • C-13-60
3ms
CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors (clinicaltrials.gov)
P1, N=108, Recruiting, Chongqing Precision Biotech Co., Ltd
New P1 trial
|
cyclophosphamide • fludarabine IV • C-13-60
7ms
CAR-T Therapy Targeting CEA in Advanced CEA-Positive Lung Cancer (clinicaltrials.gov)
P1, N=60, Recruiting, Chongqing Precision Biotech Co., Ltd | Not yet recruiting --> Recruiting
Enrollment open • IO biomarker
|
cyclophosphamide • fludarabine IV • C-13-60
7ms
CAR-T Therapy Targeting CEA in Advanced CEA-Positive Lung Cancer (clinicaltrials.gov)
P1, N=60, Not yet recruiting, Chongqing Precision Biotech Co., Ltd
New P1 trial • IO biomarker
|
cyclophosphamide • fludarabine IV • C-13-60
10ms
PBC039: A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors (clinicaltrials.gov)
P1, N=60, Active, not recruiting, Weijia Fang, MD | Recruiting --> Active, not recruiting | Trial completion date: May 2025 --> Dec 2025
Enrollment closed • Trial completion date • IO biomarker
|
CEACAM5 (CEA Cell Adhesion Molecule 5)
|
cyclophosphamide • fludarabine IV • C-13-60
10ms
Study of CEA Targeting CAR-T in the Treatment of CEA-Positive Advanced Malignant Solid Tumors (clinicaltrials.gov)
P1, N=72, Recruiting, Weijia Fang, MD
New P1 trial
|
CEACAM5 (CEA Cell Adhesion Molecule 5)
|
cyclophosphamide • fludarabine IV • C-13-60
11ms
A Clinical Trial of CEA Targeting CAR-T for CEA Positive Advanced Lung Cancer (clinicaltrials.gov)
P1, N=48, Recruiting, Chongqing Precision Biotech Co., Ltd
New P1 trial • IO biomarker
|
CEACAM5 positive
|
cyclophosphamide • fludarabine IV • C-13-60
2years
Intraperitoneal administration of carcinoembryonic antigen-directed chimeric antigen receptor T cells is a robust delivery route for effective treatment of peritoneal carcinomatosis from colorectal cancer in pre-clinical study. (PubMed, Cytotherapy)
Taken together, our data suggest that i.p. administration of CAR T cells may be a robust delivery route for effective treatment of cancer.
Preclinical • Journal • CAR T-Cell Therapy
|
CEACAM5 (CEA Cell Adhesion Molecule 5) • PSCA (Prostate Stem Cell Antigen 2)
|
C-13-60
2years
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors (clinicaltrials.gov)
P1, N=36, Recruiting, Chongqing Precision Biotech Co., Ltd | Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2023 --> Sep 2024
Trial completion date • Trial primary completion date • IO biomarker • Metastases
|
CEACAM5 (CEA Cell Adhesion Molecule 5)
|
CEACAM5 expression • CEACAM5 positive
|
cyclophosphamide • C-13-60
2years
Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors (clinicaltrials.gov)
P1, N=60, Recruiting, Chongqing Precision Biotech Co., Ltd
New P1 trial • Metastases
|
CEACAM5 positive
|
cyclophosphamide • C-13-60
2years
A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors (clinicaltrials.gov)
P1, N=30, Recruiting, Chongqing Precision Biotech Co., Ltd
New P1 trial • CAR T-Cell Therapy • Metastases
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
|
PD-L1 expression • HER-2 positive • EGFR mutation • HR positive • ALK positive • EGFR T790M • ALK fusion • EGFR positive • CEACAM5 positive
|
cyclophosphamide • C-13-60
Share via
